See more : Zip Co Limited (ZIZTF) Income Statement Analysis – Financial Results
Complete financial analysis of ImmunoGen, Inc. (IMGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ImmunoGen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Metal Coatings (India) Limited (METALCO.BO) Income Statement Analysis – Financial Results
- THC Therapeutics, Inc. (THCT) Income Statement Analysis – Financial Results
- Pacific Bay Minerals Ltd. (PBMFF) Income Statement Analysis – Financial Results
- Ambev S.A. (ABEV3.SA) Income Statement Analysis – Financial Results
- Huneed Technologies (005870.KS) Income Statement Analysis – Financial Results
ImmunoGen, Inc. (IMGN)
About ImmunoGen, Inc.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 108.78M | 108.78M | 132.30M | 82.27M | 53.82M | 115.45M | 48.63M | 60.00M | 85.54M | 59.90M | 35.54M | 16.36M | 19.31M | 13.94M | 27.99M | 40.25M | 38.21M | 32.09M | 35.72M | 25.96M | 7.63M | 5.88M | 4.48M | 11.18M | 3.70M | 600.00K | 400.00K | 500.00K | 500.00K | 900.00K | 1.70M | 2.70M | 3.40M | 1.00M | 800.00K |
| Cost of Revenue | 176.00K | 176.00K | 114.59M | 114.52M | 173.89M | 139.74M | 141.31M | 146.92M | 111.77M | 106.96M | 87.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.57M | 2.67M | 9.24M | 5.66M | 2.83M | 3.34M | 597.05K | -463.45K | -500.00K | -1.10M | -1.50M | -6.00M | 13.40M | 17.90M | -1.70M | -1.30M | 9.50M | 7.10M | 4.70M |
| Gross Profit | 108.61M | 108.61M | 17.71M | -32.25M | -120.07M | -24.29M | -92.68M | -86.91M | -26.23M | -47.06M | -51.54M | 16.36M | 19.31M | 13.94M | 27.99M | 40.25M | 34.64M | 29.42M | 26.48M | 20.30M | 4.79M | 2.54M | 3.88M | 11.64M | 4.20M | 1.70M | 1.90M | 6.50M | -12.90M | -17.00M | 3.40M | 4.00M | -6.10M | -6.10M | -3.90M |
| Gross Profit Ratio | 99.84% | 99.84% | 13.38% | -39.20% | -223.11% | -21.04% | -190.60% | -144.85% | -30.66% | -78.57% | -145.03% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 90.65% | 91.69% | 74.14% | 78.20% | 62.84% | 43.21% | 86.67% | 104.15% | 113.51% | 283.33% | 475.00% | 1,300.00% | -2,580.00% | -1,888.89% | 200.00% | 148.15% | -179.41% | -610.00% | -487.50% |
| Research & Development | 213.37M | 213.37M | 114.59M | 114.52M | 173.89M | 139.74M | 141.31M | 146.92M | 111.77M | 106.96M | 87.07M | 69.19M | 63.45M | 50.28M | 45.90M | 60.01M | 45.84M | 40.91M | 30.54M | 22.22M | 23.43M | 17.69M | 15.21M | 8.88M | 6.10M | 6.60M | 7.40M | 9.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 43.81M | 38.60M | 38.49M | 36.72M | 33.91M | 38.53M | 36.92M | 28.23M | 24.47M | 21.47M | 20.42M | 16.04M | 14.90M | 13.90M | 14.35M | 11.03M | 9.90M | 8.77M | 6.63M | 5.96M | 5.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 72.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 116.13M | 116.13M | 38.60M | 38.49M | 36.72M | 33.91M | 38.53M | 36.92M | 28.23M | 24.47M | 21.47M | 20.42M | 16.04M | 14.90M | 13.90M | 14.35M | 11.03M | 9.90M | 8.77M | 6.63M | 5.96M | 5.40M | 4.48M | 3.06M | 1.80M | 1.70M | 2.20M | 1.80M | 3.00M | 4.50M | 20.20M | 18.00M | 1.40M | 1.40M | 1.00M |
| Other Expenses | 3.35M | 3.35M | 1.21M | 5.01M | 3.33M | 2.61M | 0.00 | 304.00K | -848.00K | 167.00K | 198.00K | 64.68M | 56.20M | 44.92M | 38.34M | 44.98M | 23.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 463.45K | 500.00K | 1.10M | 1.50M | 6.00M | 3.40M | 2.00M | 1.70M | 1.30M | 1.10M | 700.00K | 300.00K |
| Operating Expenses | 329.50M | 329.50M | 153.19M | 153.01M | 210.60M | 173.65M | 43.54M | 183.83M | 140.00M | 131.43M | 108.54M | 89.61M | 79.49M | 65.18M | 59.80M | 74.36M | 56.87M | 50.81M | 39.30M | 28.86M | 29.39M | 23.10M | 19.69M | 12.40M | 8.40M | 9.40M | 11.10M | 17.40M | 6.40M | 6.50M | 21.90M | 19.30M | 2.50M | 2.10M | 1.30M |
| Cost & Expenses | 329.68M | 329.68M | 153.19M | 153.01M | 210.60M | 173.65M | 184.85M | 183.83M | 140.00M | 131.43M | 108.54M | 89.61M | 79.49M | 65.18M | 59.80M | 74.36M | 60.44M | 53.47M | 48.54M | 34.51M | 32.22M | 26.44M | 20.29M | 11.94M | 7.90M | 8.30M | 9.60M | 11.40M | 19.80M | 24.40M | 20.20M | 18.00M | 12.00M | 9.20M | 6.00M |
| Interest Income | 4.34M | 51.00K | 729.00K | 4.42M | 0.00 | 0.00 | 20.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.17M | 4.17M | 23.20M | 16.97M | 10.73M | 16.72M | 0.00 | 20.13M | 5.44M | 0.00 | 0.00 | 62.00K | 0.00 | 0.00 | 221.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 3.35M | -1.08M | 115.80M | 26.45M | 7.41M | 5.96M | 6.01M | 5.33M | 5.51M | 4.60M | 4.64M | 4.63M | 4.94M | 4.84M | 5.00M | 3.93M | 3.15M | 2.69M | 2.22M | 1.29M | 1.13M | 984.76K | 612.82K | 463.45K | 500.00K | 1.10M | 1.50M | 6.00M | 3.40M | 2.00M | 1.70M | 1.30M | 1.10M | 700.00K | 300.00K |
| EBITDA | -217.55M | -217.55M | -19.68M | -65.73M | -153.45M | -55.60M | -125.20M | -123.53M | -55.30M | -71.53M | -73.01M | -73.20M | -62.10M | -51.29M | -31.60M | -32.30M | -22.35M | -18.99M | -10.53M | -8.59M | -25.42M | -20.57M | -15.66M | -366.61K | -3.80M | -6.60M | -7.90M | -3.00M | -15.90M | -21.50M | -16.80M | -14.00M | -7.50M | -7.50M | -4.90M |
| EBITDA Ratio | -199.98% | -199.98% | -14.88% | -79.89% | -285.15% | -48.16% | -257.46% | -205.87% | -64.65% | -119.43% | -205.46% | -447.48% | -321.69% | -367.88% | -112.89% | -80.25% | -58.48% | -59.19% | -29.47% | -33.09% | -333.30% | -349.63% | -349.69% | -3.28% | -102.70% | -1,100.00% | -1,975.00% | -600.00% | -3,180.00% | -2,388.89% | -988.24% | -518.52% | -220.59% | -750.00% | -612.50% |
| Operating Income | -220.89M | -220.89M | -135.49M | -92.17M | -160.48M | -58.98M | -131.21M | -123.83M | -54.46M | -71.53M | -73.01M | -73.26M | -60.19M | -51.24M | -31.82M | -34.11M | -22.23M | -21.39M | -12.82M | -8.56M | -24.59M | -20.56M | -15.81M | -761.00K | -4.20M | -7.70M | -9.20M | -10.90M | -19.30M | -23.50M | -18.50M | -15.30M | -8.60M | -8.20M | -5.20M |
| Operating Income Ratio | -203.06% | -203.06% | -102.41% | -112.04% | -298.20% | -51.09% | -269.83% | -206.37% | -63.66% | -119.43% | -205.46% | -447.86% | -311.77% | -367.46% | -113.68% | -84.75% | -58.16% | -66.65% | -35.90% | -32.97% | -322.39% | -349.41% | -353.01% | -6.81% | -113.51% | -1,283.33% | -2,300.00% | -2,180.00% | -3,860.00% | -2,611.11% | -1,088.24% | -566.67% | -252.94% | -820.00% | -650.00% |
| Total Other Income/Expenses | -818.00K | -14.23M | -21.99M | -11.96M | -8.36M | -37.03M | -25.52M | -19.83M | -6.28M | 167.00K | 198.00K | -62.00K | 1.91M | 58.00K | -221.00K | 2.12M | 3.27M | 3.57M | 1.90M | 2.69M | 4.65M | 6.05M | 6.34M | 523.44K | 100.00K | 100.00K | 200.00K | -5.60M | -600.00K | -200.00K | -100.00K | 0.00 | -100.00K | -100.00K | -100.00K |
| Income Before Tax | -221.71M | -221.71M | -44.37M | -104.13M | -167.87M | -96.01M | -156.73M | -143.66M | -60.74M | -71.36M | -72.81M | -73.32M | -58.27M | -51.18M | -32.04M | -31.99M | -18.95M | -17.82M | -10.92M | -5.87M | -19.95M | -14.50M | -9.47M | -237.56K | -4.10M | -7.60M | -9.00M | -16.50M | -19.90M | -23.70M | -18.60M | -15.30M | -8.70M | -8.30M | -5.30M |
| Income Before Tax Ratio | -203.81% | -203.81% | -33.54% | -126.57% | -311.94% | -83.17% | -322.31% | -239.42% | -71.01% | -119.15% | -204.90% | -448.24% | -301.86% | -367.04% | -114.47% | -79.49% | -49.60% | -55.53% | -30.58% | -22.62% | -261.49% | -246.51% | -211.49% | -2.12% | -110.81% | -1,266.67% | -2,250.00% | -3,300.00% | -3,980.00% | -2,633.33% | -1,094.12% | -566.67% | -255.88% | -830.00% | -662.50% |
| Income Tax Expense | 1.22M | 1.22M | 22.31M | 17.96M | 7.39M | 37.03M | 0.00 | 19.83M | 6.28M | -167.00K | -198.00K | 62.00K | -1.91M | -265.00K | -100.00K | 27.00K | 35.00K | 17.00K | 29.00K | 45.49K | 35.13K | 127.81K | 82.60K | 237.56K | 4.10M | 7.60M | 9.00M | 16.50M | 19.90M | 23.70M | 18.60M | 15.30M | 100.00K | 8.30M | 5.30M |
| Net Income | -222.93M | -222.93M | -66.68M | -122.09M | -167.87M | -96.01M | -156.73M | -143.66M | -60.74M | -71.36M | -72.81M | -73.32M | -58.27M | -50.91M | -31.94M | -32.02M | -18.99M | -17.83M | -10.95M | -5.92M | -19.98M | -14.63M | -15.29M | -237.56K | -4.10M | -7.60M | -9.00M | -16.50M | -19.90M | -23.70M | -18.60M | -15.30M | -8.80M | -8.30M | -5.30M |
| Net Income Ratio | -204.93% | -204.93% | -50.40% | -148.40% | -311.94% | -83.17% | -322.31% | -239.42% | -71.01% | -119.15% | -204.90% | -448.24% | -301.86% | -365.14% | -114.11% | -79.55% | -49.69% | -55.58% | -30.66% | -22.80% | -261.95% | -248.68% | -341.36% | -2.12% | -110.81% | -1,266.67% | -2,250.00% | -3,300.00% | -3,980.00% | -2,633.33% | -1,094.12% | -566.67% | -258.82% | -830.00% | -662.50% |
| EPS | -0.88 | -0.88 | -0.38 | -0.82 | -1.20 | -0.98 | -1.80 | -1.65 | -0.71 | -0.83 | -0.87 | -0.95 | -0.85 | -0.87 | -0.63 | -0.75 | -0.45 | -0.43 | -0.27 | -0.15 | -0.48 | -0.37 | -0.42 | -0.01 | -0.16 | -0.31 | -0.50 | -1.32 | -1.58 | -2.09 | -1.76 | -1.58 | -1.28 | -1.46 | -3.36 |
| EPS Diluted | -0.88 | -0.88 | -0.38 | -0.82 | -1.20 | -0.98 | -1.80 | -1.65 | -0.71 | -0.83 | -0.87 | -0.95 | -0.85 | -0.87 | -0.63 | -0.75 | -0.45 | -0.43 | -0.27 | -0.15 | -0.48 | -0.37 | -0.42 | -0.01 | -0.16 | -0.31 | -0.50 | -1.32 | -1.58 | -2.09 | -1.76 | -1.58 | -1.28 | -1.46 | -3.36 |
| Weighted Avg Shares Out | 253.33M | 253.63M | 176.15M | 148.31M | 139.95M | 98.07M | 87.08M | 86.98M | 86.04M | 85.48M | 84.06M | 76.81M | 68.92M | 58.85M | 51.07M | 42.97M | 41.76M | 41.18M | 40.87M | 40.65M | 41.91M | 39.62M | 36.68M | 29.52M | 25.53M | 24.21M | 17.86M | 12.50M | 12.57M | 11.34M | 10.57M | 9.68M | 6.88M | 5.68M | 1.58M |
| Weighted Avg Shares Out (Dil) | 253.63M | 253.63M | 176.15M | 148.31M | 139.95M | 98.07M | 87.08M | 86.98M | 86.04M | 85.48M | 84.06M | 76.81M | 68.92M | 58.85M | 51.07M | 42.97M | 41.76M | 41.18M | 40.87M | 40.65M | 41.91M | 39.62M | 36.68M | 32.85M | 25.53M | 24.21M | 17.86M | 12.50M | 12.62M | 11.34M | 10.57M | 9.68M | 6.88M | 5.68M | 1.58M |
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Canaccord Genuity 43rd Annual Growth Conference
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming Canaccord Genuity 43rd Annual Growth...
ImmunoGen (IMGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
ImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates.
ImmunoGen's ELAHERE Has Likely Blockbuster Potential
ELAHERE only has accelerated approval from the FDA; the confirmatory trial was positive. The company's lead product seems to have nowhere near the insurance coverage that management claims. However, the antibody-drug conjugate is better than chemotherapy, and will likely dominate...
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Operating Results
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Monday, July 31, 2023...
ImmunoGen (IMGN) Crossed Above the 20-Day Moving Average: What That Means for Investors
ImmunoGen (IMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IMGN broke through the 20-day moving average, which suggests a short-term bullish trend.
ImmunoGen: Comprehensive MIRASOL Data Reinforces Elahere's Potential
ImmunoGen's Q1 2023 revenue increased to $49.9 million, primarily due to sales of Elahere and an upfront fee from Vertex Pharmaceuticals. The company plans to close a $325 million public offering. The MIRASOL trial confirmed Elahere's potential as a transformative...
3 Biotech Stocks to Make Your ‘Get Rich' Dreams Come True
Navigating the choppy waters in the biotech sphere can be daunting, which makes it a challenge to hunt for the top high return biotech stocks. The journey to market approval, encumbered by volatile clinical trials and regulatory roadblocks, can be...
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
5 Sizzling Stocks That Are Outperformers in the Market This Year
The scorching 2023 S&P 500 market rally has been red hot. As a result, we're seeing quite a few sizzling market outperformers.
Source: https://incomestatements.info
Category: Stock Reports